Streetbeat News

BTMD

biote Corp.

Industry

Medical - Care Facilities

biote Corp. operates in medical practice-building business within the hormone optimization space. The company offers a platform for Biote-certified practitioners to optimize imbalances in their patient's hormone, vitamin, and mineral levels, as well as prescribe bioidentical hormone therapies and recommend dietary supplements. It also sells Biote-branded dietary supplements; and sterile pellet insertion kits for men and women. The company was founded in 2011 and is headquartered in Irvine, Texas.

Open

N/A

Mkt cap

N/A

Volume

N/A

High

N/A

P/E Ratio

N/A

52-wk high

N/A

Low

N/A

Div yield

N/A

52-wk low

N/A

Biote shares have experienced an increase in trading volume and price following the announcement of their Q4 GAAP EPS results, which exceeded market expectations.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 5:52 pm

Roth MKM analyst George Kelly has reiterated a Buy rating on Biote (NASDAQ:BTMD) and increased the price target from $8 to $9.

Portfolio Pulse from Benzinga Newsdesk

March 13, 2024 | 3:12 pm

Biote has reaffirmed its 2024 financial guidance, expecting revenues between $200M-$204M and Adjusted EBITDA between $60M-$63M. The company anticipates low-single digit revenue growth in H1 2024, with a significant improvement in H2, attributed to changes in the nutraceutical distribution channel and seasonal promotions.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:52 pm

Biote (NASDAQ:BTMD) reported Q4 earnings with an EPS of $0.18, surpassing the estimate of $0.08 by 125%. Revenue increased by $1.22 million year-over-year. Despite beating EPS estimates in the past, such as in Q3 2023, the share price dropped 24% the following day.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 8:15 pm

Biote (NASDAQ:BTMD) reported Q4 2023 earnings of $0.18 per share, surpassing the $0.08 estimate, but its sales of $45.703M slightly missed the $45.740M estimate. Year-over-year, earnings remained stable while sales grew by 2.74%.

Portfolio Pulse from Benzinga Newsdesk

March 12, 2024 | 8:13 pm

Numerous companies are scheduled to report their earnings on March 12, 2024, with expectations ranging from significant profits to losses. Key highlights include Aurora Mobile, MINISO Group, and Archer-Daniels Midland among others, projecting varied financial outcomes for their respective quarters.

Portfolio Pulse from Benzinga Insights

March 12, 2024 | 9:35 am

Biote (NASDAQ:BTMD) is scheduled to release its quarterly earnings report on March 12, 2024, with an estimated EPS of $0.08. Historical data shows mixed reactions to past earnings, with significant price changes following the announcements. Shares have risen 16.74% over the last year, trading at $5.64 as of March 08.

Portfolio Pulse from Benzinga Insights

March 11, 2024 | 6:01 pm

Biote Corp. (NASDAQ:BTMD) has reached an agreement to resolve litigation with its founder, Dr. Gary S. Donovitz, by repurchasing approximately 18.4 million of its Class A shares and Paired Interests from Donovitz at $4.17 per share, totaling about $76.9 million. This settlement includes a mutual release of all claims, termination of the founder advisory agreement, and a two-year non-compete and non-solicitation agreement with Donovitz. The repurchase is supported by Biote's strong capital position and is expected to be accretive to shareholder value.

Portfolio Pulse from Benzinga Newsdesk

February 20, 2024 | 9:14 pm

Jefferies analyst Kaumil Gajrawala initiates coverage on Biote (NASDAQ:BTMD) with a Buy rating and a price target of $6.55.

Portfolio Pulse from Benzinga Newsdesk

February 01, 2024 | 1:02 pm

Biote Corp. (NASDAQ:BTMD) has announced a $20 million share repurchase program, authorizing the management to buy back shares in the open market or through private transactions. This move reflects the company's confidence in its growth and financial strength. The repurchase timing will depend on market conditions and other factors, and the program may be adjusted or discontinued at any time.

Portfolio Pulse from Benzinga Newsdesk

January 25, 2024 | 9:35 pm

All corporate logos and prices are for illustrative purposes only and are not a recommendation, an offer to sell, or a solicitation of an offer to buy any security.